Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study
- Conditions
- Functional Dyspepsia
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT01513785
- Locations
- 🇨🇳
GI Division, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, Shanghai, China
Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections
- Conditions
- Pregnancy Complications
- Interventions
- Drug: Preventive antibiotic treatment- CEPHALEXINDrug: PREVENTIVE TREATMENT- CEFUROXIMEDrug: PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 220
- Registration Number
- NCT01507974
- Locations
- 🇮🇱
Dep of OG/GYN, Emek Medical Center, Afula, Israel
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
- Conditions
- H. Pylori Infection
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 650
- Registration Number
- NCT01505127
Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota
- Conditions
- Healthy Volunteers
- Interventions
- Dietary Supplement: Saccharomyces boulardii
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT01473368
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 62
- Registration Number
- NCT01442688
- Locations
- 🇺🇸
PRA International, Lenexa, Kansas, United States
Bioavailability of Amoxicillin Dissolved in Human Milk
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 16
- Registration Number
- NCT01435824
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Amoxicillin Bioequivalence Study Brazil - Fast
- Conditions
- Infections, Bacterial
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT01431989
- Locations
- 🇧🇷
GSK Investigational Site, Goiania, Goiás, Brazil
Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
- Conditions
- Human Gut Microbiota
- Interventions
- Dietary Supplement: Trametes versicolor extractDietary Supplement: Saccharomyces boulardii
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT01414010
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Special Drug Use Investigation for CLAVAMOX® (Amoxicillin/Clavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 363
- Registration Number
- NCT01406275
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
- First Posted Date
- 2011-07-22
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
- Target Recruit Count
- 561
- Registration Number
- NCT01399723
- Locations
- 🇰🇪
New Nyanza Provincial General Hospital, Kisumu, Nyanza, Kenya
🇰🇪Kisumu East District Hospital, Kisumu, Nyanza, Kenya
🇰🇪Kerugoya District Hospital, Kerugoya, Central, Kenya
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.